Meridian Management’s Co-Diagnostics CODX Stock Holding History

Meridian Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-333	Closed	-$93K	–	80
2020 Q4	$93K	Buy	+333	New	+$123K	0.03%	78

Other funds holding CODX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Meridian Management's CODX Position: Q1 2021 in Review

Meridian Management sold out of Co-Diagnostics (CODX) in Q1 2021, closing a stake of 333 shares — an estimated $93K sold.

Meridian Management first reported a position in CODX in Q4 2020 and held it in 1 quarter. The position peaked at $93K in Q4 2020. 95 funds tracked by Wall St. Rank hold CODX as of Q1 2021.

Meridian Management reported no remaining Co-Diagnostics position as of Q1 2021 after selling out during the quarter.
Meridian Management sold 333 Co-Diagnostics shares in Q1 2021, an estimated $93K.
Meridian Management first reported a position in Co-Diagnostics in Q4 2020 and held it in 1 quarter.
Meridian Management's Co-Diagnostics position peaked at $93K in Q4 2020.
95 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2021.

Based on Meridian Management's 13F filing for Q1 2021, filed 10 May 2021.